Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: AurumRabosa who wrote (911)	4/4/2000 11:12:00 PM
From: RCMac	Respond to of 52153

The $100 billion valuation for biotechs in the aggregate is way out of date. Although Cynthia Robbins-Roth's piece is in the current Forbes, it clearly was written, or at least finalized, last fall sometime - for one example, the quoted performance numbers are through 6/30/99. For a more current valuation, see Peter Suzman's post 538 of January 23 on this thread: Message 12651676 Even this valuation -- $390 billion - was before the real biotech levitation of February and early March, only a fraction of which has been given back; and before the great flood of new biotech financings after January 23 (many documented by Nigel Bates, Rick Harmon and others on SI, mostly on the Biotechnology Value Fund thread: Subject 19115 ) which has tremendously added to stock values in the sector. -- RCM